Index - P/E - EPS (ttm) -1.45 Insider Own 0.02% Shs Outstand 1.15B Perf Week 9.20%
Market Cap 16.80B Forward P/E 5.44 EPS next Y 2.70 Insider Trans -81.22% Shs Float 1.15B Perf Month -6.59%
Income -1639.00M PEG - EPS next Q 0.46 Inst Own 59.23% Short Float 2.83% Perf Quarter -32.70%
Sales 16.53B P/S 1.02 EPS this Y 3.02% Inst Trans 4.24% Short Ratio 2.47 Perf Half Y -19.33%
Book/sh 4.74 P/B 3.09 EPS next Y 5.10% ROA -3.96% Short Interest 32.39M Perf Year 13.86%
Cash/sh 2.88 P/C 5.09 EPS next 5Y 6.26% ROE -25.44% 52W Range 12.47 - 22.80 Perf YTD -33.46%
Dividend Est. - P/FCF 8.24 EPS past 5Y -9.62% ROI -7.56% 52W High -35.68% Beta 0.65
Dividend TTM - Quick Ratio 0.75 Sales past 5Y -0.32% Gross Margin 48.70% 52W Low 17.65% ATR (14) 0.70
Dividend Ex-Date Nov 27, 2017 Current Ratio 0.98 EPS Y/Y TTM -206.85% Oper. Margin 20.27% RSI (14) 50.93 Volatility 2.93% 5.08%
Employees 36167 Debt/Eq 3.38 Sales Y/Y TTM 4.34% Profit Margin -9.91% Recom 1.73 Target Price 23.67
Option/Short Yes / Yes LT Debt/Eq 3.03 EPS Q/Q -147.24% Payout - Rel Volume 0.55 Prev Close 14.29
Sales Surprise 2.00% EPS Surprise 0.38% Sales Q/Q -6.32% Earnings May 07 BMO Avg Volume 13.13M Price 14.66
SMA20 3.39% SMA50 -4.90% SMA200 -16.47% Trades
Volume 4,562,423 Change 2.62%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-10-24 Upgrade Argus
Hold → Buy
$20
Mar-08-24 Upgrade JP Morgan
Underweight → Neutral
$14
Feb-12-24 Upgrade Piper Sandler
Neutral → Overweight
$12 → $19
Jan-23-24 Upgrade Jefferies
Hold → Buy
$10 → $14
Jan-03-24 Upgrade Piper Sandler
Underweight → Neutral
$8 → $12
Dec-18-23 Initiated HSBC Securities
Buy
$13
Nov-27-23 Upgrade UBS
Neutral → Buy
$11 → $13
Jul-06-23 Upgrade UBS
Sell → Neutral
$7 → $8
May-25-23 Initiated Morgan Stanley
Equal-Weight
$10
May-18-23 Upgrade Evercore ISI
In-line → Outperform
Jan-19-23 Downgrade Jefferies
Buy → Hold
$10 → $12
Nov-14-22 Downgrade JP Morgan
Neutral → Underweight
$11 → $10
Nov-04-22 Downgrade UBS
Neutral → Sell
Oct-21-22 Resumed Jefferies
Buy
$10
Aug-05-22 Upgrade BofA Securities
Neutral → Buy
$10 → $13
Jun-14-22 Resumed UBS
Neutral
$10
May-17-22 Upgrade BofA Securities
Underperform → Neutral
$9
May-04-22 Downgrade Piper Sandler
Neutral → Underweight
$11 → $7
Apr-05-22 Upgrade Barclays
Equal Weight → Overweight
$11 → $13
Mar-25-22 Upgrade Bernstein
Mkt Perform → Outperform
$11
Show Previous Ratings
Today 07:46AM
Apr-21-25 08:21AM
03:51AM
Apr-17-25 08:03AM
Apr-16-25 04:38AM
11:14AM
Loading…
Apr-15-25 11:14AM
07:15AM
Apr-13-25 03:06AM
Apr-11-25 03:03PM
Apr-10-25 07:46PM
(Morningstar Research) -9.46%
Apr-09-25 03:59PM
Apr-08-25 09:35AM
Apr-07-25 08:00AM
07:30AM
Apr-04-25 11:10PM
04:35PM
Loading…
Apr-03-25 04:35PM
02:19PM
Apr-02-25 01:06PM
Apr-01-25 01:05PM
10:02AM
Mar-31-25 01:00PM
Mar-30-25 05:00AM
Mar-28-25 09:44AM
06:11AM
Mar-27-25 04:30PM
04:30PM
Mar-24-25 05:06AM
Mar-22-25 05:20PM
Mar-21-25 07:21AM
Mar-19-25 07:00AM
03:22PM
Loading…
Mar-18-25 03:22PM
(Investor's Business Daily)
Mar-14-25 03:27AM
Mar-11-25 07:08AM
Mar-03-25 04:30PM
Mar-01-25 05:04PM
02:52PM
Feb-28-25 02:11AM
Feb-27-25 08:34AM
08:00AM
Feb-25-25 05:03PM
04:00PM
02:06PM
Feb-24-25 08:22AM
06:38AM
(Pharmaceutical Technology)
06:19AM
05:23AM
Feb-22-25 02:20AM
Feb-21-25 06:00AM
Feb-20-25 05:06AM
Feb-19-25 08:28AM
Feb-18-25 04:30PM
11:27AM
06:00AM
Feb-14-25 06:32PM
Feb-10-25 12:33PM
06:45AM
Jan-31-25 08:00AM
(Investor's Business Daily)
02:14AM
Jan-30-25 07:05AM
Jan-29-25 03:37PM
(Morningstar Research) -13.89%
02:26PM
02:15PM
01:18PM
(Investor's Business Daily)
01:18PM
(Investor's Business Daily)
12:43PM
11:39AM
09:32AM
(Investor's Business Daily)
09:30AM
07:00AM
Jan-27-25 06:00AM
Jan-23-25 07:44AM
(Pharmaceutical Technology)
Jan-18-25 08:20AM
Jan-17-25 09:46AM
Jan-13-25 11:55AM
01:00AM
Jan-10-25 08:30AM
Jan-09-25 12:31PM
Jan-08-25 04:10PM
(Investor's Business Daily)
Jan-03-25 10:47AM
Dec-28-24 09:27AM
Dec-24-24 04:51AM
04:05AM
Dec-23-24 04:30PM
Dec-21-24 07:58AM
Dec-20-24 04:30PM
04:51AM
Dec-19-24 07:45AM
Dec-18-24 02:50PM
07:08AM
06:39AM
05:26AM
Dec-17-24 09:47PM
(Morningstar Research) +26.47%
04:36PM
04:10PM
(Investor's Business Daily)
01:20PM
12:00PM
11:55AM
(Investor's Business Daily)
11:51AM
11:51AM
(The Wall Street Journal)
10:37AM
(Investor's Business Daily)
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Daniell Richard Exec. VP, European Commercial Mar 05 '25 Sale 15.91 70,961 1,128,642 48,384 Mar 07 04:05 PM Hughes Eric A See "Remarks" Mar 04 '25 Sale 15.73 15,174 238,757 8,077 Mar 06 04:11 PM Hughes Eric A See "Remarks" Mar 05 '25 Sale 15.91 8,077 128,531 0 Mar 06 04:11 PM Daniell Richard Exec. VP, European Commercial Mar 04 '25 Sale 15.73 91,608 1,441,415 7,108 Mar 06 04:06 PM Daniell Richard Exec. VP, European Commercial Mar 05 '25 Sale 15.91 48,764 775,991 0 Mar 06 04:06 PM Francis Richard D President and CEO Mar 04 '25 Sale 15.73 15,514 244,107 280,042 Mar 06 04:03 PM Francis Richard D President and CEO Mar 05 '25 Sale 15.91 8,259 131,427 271,783 Mar 06 04:03 PM Daniell Richard Officer Mar 05 '25 Proposed Sale 15.83 70,961 1,123,585 Mar 05 04:29 PM Daniell Richard Exec. VP, European Commercial Mar 03 '25 Sale 16.19 49,314 798,172 12,936 Mar 05 04:12 PM Daniell Richard Exec. VP, European Commercial Mar 04 '25 Sale 15.56 12,936 201,253 0 Mar 05 04:12 PM Hughes Eric A See "Remarks" Mar 03 '25 Sale 16.19 19,726 319,275 5,174 Mar 05 04:08 PM Hughes Eric A See "Remarks" Mar 04 '25 Sale 15.56 5,174 80,495 0 Mar 05 04:08 PM Francis Richard D President and CEO Mar 03 '25 Sale 16.19 24,892 402,889 251,783 Mar 05 04:04 PM Francis Richard D President and CEO Mar 04 '25 Sale 15.56 6,450 100,347 245,333 Mar 05 04:04 PM Fox Christine Officer Mar 04 '25 Proposed Sale 16.00 6,181 98,896 Mar 04 07:02 PM McAvoy David R. Officer Mar 04 '25 Proposed Sale 16.00 4,827 77,232 Mar 04 06:57 PM Hughes Eric A Officer Mar 04 '25 Proposed Sale 16.00 23,251 372,016 Mar 04 06:44 PM Daniell Richard Officer Mar 04 '25 Proposed Sale 16.00 86,400 1,382,400 Mar 04 06:37 PM Francis Richard D Officer Mar 04 '25 Proposed Sale 16.00 23,773 380,368 Mar 04 06:30 PM Kalif Eliyahu Sharon EVP, Chief Financial Officer Feb 28 '25 Sale 16.21 55,750 903,462 147,941 Mar 04 04:02 PM Francis Richard D Officer Mar 03 '25 Proposed Sale 16.46 31,342 515,889 Mar 03 01:14 PM Hughes Eric A Officer Mar 03 '25 Proposed Sale 16.46 24,900 409,854 Mar 03 01:07 PM Daniell Richard Officer Mar 03 '25 Proposed Sale 16.46 62,250 1,024,635 Mar 03 12:59 PM Kalif Eliyahu Sharon Officer Feb 28 '25 Proposed Sale 16.21 55,750 903,463 Feb 28 11:52 AM Francis Richard D President and CEO Feb 18 '25 Sale 16.95 75,506 1,279,661 209,444 Feb 19 04:03 PM Francis Richard D Officer Feb 18 '25 Proposed Sale 16.95 75,506 1,279,661 Feb 18 12:38 PM Sabag Mark See "Remarks" Feb 12 '25 Sale 16.25 177,626 2,886,565 204,964 Feb 14 04:03 PM Sabag Mark Officer Feb 12 '25 Proposed Sale 16.25 177,626 2,886,555 Feb 13 08:06 AM MIGNONE ROBERTO Director Dec 20 '24 Sale 22.01 286,000 6,294,031 695,000 Dec 26 04:02 PM Bridger Management, LLC (1) Shareholder Dec 20 '24 Proposed Sale 21.31 286,000 6,094,660 Dec 20 07:03 PM Fox Christine EVP, Head of U.S. Commercial Nov 20 '24 Sale 16.87 19,388 327,085 44,104 Nov 21 04:04 PM Fox Christine Officer Nov 20 '24 Proposed Sale 16.87 19,388 327,085 Nov 20 11:39 AM Daniell Richard Exec. VP, European Commercial Aug 12 '24 Sale 17.30 98,943 1,711,447 0 Aug 13 04:09 PM Grant Angus EVP, Business Development Aug 09 '24 Sale 17.28 4,065 70,243 8,848 Aug 13 04:06 PM Hughes Eric A See "Remarks" Aug 09 '24 Sale 17.38 45,060 782,972 0 Aug 13 04:02 PM Daniell Richard Officer Aug 12 '24 Proposed Sale 17.30 98,943 1,711,444 Aug 12 04:09 PM Hughes Eric A Officer Aug 09 '24 Proposed Sale 17.38 45,060 782,974 Aug 12 03:59 PM Grant Angus Officer Aug 09 '24 Proposed Sale 17.28 4,065 70,243 Aug 09 03:59 PM Hughes Eric A See "Remarks" Aug 01 '24 Sale 17.25 24,537 423,280 45,060 Aug 05 07:35 AM Hughes Eric A Officer Aug 01 '24 Proposed Sale 17.25 24,537 423,281 Aug 01 04:00 PM MIGNONE ROBERTO Director Jun 18 '24 Sale 17.03 519,000 8,838,570 981,000 Jun 21 04:05 PM Weiss Amir Chief Accounting Officer May 15 '24 Sale 16.80 15,500 260,417 17,814 May 17 07:41 AM Weiss Amir Chief Accounting Officer May 16 '24 Sale 16.65 12,635 210,377 5,179 May 17 07:41 AM Conway Vikki L See "Remarks" May 13 '24 Sale 16.74 15,219 254,807 0 May 15 08:36 AM
